Buprenorphine, an opioid that is a long-acting partial opiate agonist, is an efficacious treatment for opiate dependence that is growing in popularity. Nevertheless, evidence suggests that many patients will lapse within the first week of treatment and that lapses are often associated with withdrawal-related or emotional distress. Recent research suggests that individuals’ reactions to this distress may represent an important treatment target. In the current study, we describe the development and outcomes from a preliminary pilot evaluation (N = 5) of a novel distress tolerance (DT) treatment for individuals initiating buprenorphine. This treatment incorporates exposure-based and acceptance-based treatment approaches that we have previously applied to the treatment of tobacco dependence. Results from this pilot study establish the feasibility and acceptability of this approach. We are now conducting a randomized controlled trial of this treatment that we hope will yield clinically significant findings and offer clinicians an efficacious behavioral treatment to complement the effects of buprenorphine.
AmatoL.MinozziS.DavoliM.VecchiS. (2011). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. The Cochrane Database of Systematic Reviews, Oct 5, (10), CD004147.
2.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3.
BakerA.KochanN.DixonJ.WodakA.HeatherN. (1995). HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment. Addiction, 90, 545-554.
4.
BakerT. B.PiperM. E.McCarthyD. E.MajeskieM. R.FioreM. C. (2004). Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychological Review, 111, 33-51.
5.
BeckerB.J. (1988). Synthesizing standardized mean-change measures. British Journal of Mathematical and Statistical Psychology, 41, 257-278.
6.
BlockJ. A. (2002). Acceptance or change of private experiences: A comparative analysis in college students with public speaking anxiety (Unpublished doctoral dissertation) University at Albany, State University of New York, Albany.
7.
BondF. W.BunceD. (2000). Mediators of change in emotion-focused and problem-focused worksite stress management interventions. Journal of Occupational Health Psychology, 5, 156-163.
8.
BondF. W.HayesS. C.BaerR. A.CarpenterK. M.GuenoleN.OrcuttH. K.. . . ZettleR. D. (2011). Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: A revised measure of psychological inflexibility and experiential avoidance. Behavior Therapy, 42, 676-688.
9.
BoothbyL. A.DoeringP. L. (2007). Buprenorphine for the treatment of opioid dependence. American Journal of Health-System Pharmacy, 64, 266-272.
10.
BorkovecT. D.CostelloE. (1993). Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology, 61, 611-619.
BrickerJ. B.MannS. L.MarekP. M.LiuJ.PetersonA. V. (2010). Telephone-delivered acceptance and commitment therapy for adult smoking cessation: A feasibility study. Nicotine & Tobacco Research, 12, 454-458.
13.
BrownR. A.LejuezC. W.KahlerC. W.StrongD. R. (2002). Distress tolerance and duration of past smoking cessation attempts. Journal of Abnormal Psychology, 111, 180-185.
14.
BrownR. A.LejuezC. W.StrongD. R.KahlerC. W.ZvolenskyM. J.CarpenterL. L.. . . & PriceL. H. (2009). A prospective examination of distress tolerance and early smoking lapse in adult self-quitters. Nicotine & Tobacco Research, 11, 493-502.
15.
BrownR. A.PalmK. M.StrongD. R.LejuezC. W.KahlerC. W.ZvolenskyM. J.. . . GiffordE. V. (2008). Distress tolerance treatment for early-lapse smokers: Rationale, program description, and preliminary findings. Behavior Modification, 32, 302-332.
16.
BrownR. A.PalmK. M.StrongD. R.LejuezC. W.ZvolenskyM.GiffordE. V.HayesS. C. (2011). Efficacy of distress tolerance/ACT treatment vs. standard behavioral treatment for early lapse smokers. Washington, DC: Annual Meeting of the Society for Behavioral Medicine.
17.
BrownR. A.ReedK. M. P.BloomE. L.MinamiH.StrongD. R.LejuezC. W.. . . HayesS. C. (2013). Development and preliminary randomized controlled trial of a distress tolerance treatment for smokers with a history of early lapse. Nicotine & Tobacco Research, 15, 2005-2015.
18.
ButlerM.KaneR. L.McAlpineD.KatholR. G.FuS. S.HagedornH.WiltT. J. (2008). Integration of mental health/substance abuse and primary care (Evidence Report/Technology Assessment, No. 1-362, Rockville, MD: Agency for Healthcare Research and Quality (US) ).
19.
CaplehornJ. R.DaltonM. S.CluffM. C.PetrenasA. M. (1994). Retention in methadone maintenance and heroin addicts’ risk of death. Addiction, 89, 203-209.
20.
ChamblessD. L.TranG. Q.GlassC. R. (1997). Predictors of response to cognitive-behavioral group therapy for social phobia. Journal of Anxiety Disorders, 11, 221-240.
21.
CollinsJ.HyerL. (1986). Treatment expectancy among psychiatric inpatients. Journal of Clinical Psychology, 42, 562-569.
22.
ConnockM.Juarez-GarciaA.JowettS.FrewE.LiuZ.TaylorR. J.. . . TaylorR. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment, 11, 1-171; iii-iv.
23.
CunninghamC.GiovannielloA.SacajiuG.WhitleyS.MundP.BeilR.SohlerN. (2008). Buprenorphine treatment in an urban community health center: What to expect. Family Medicine, 40, 500-506.
24.
DiehrM. C.HeatonR. K.MillerW.GrantI. (1998). The Paced Auditory Serial Addition Task (PASAT): Norms for age, education, and ethnicity. Assessment, 5, 375-387.
25.
Fals-StewartW.O’FarrellT. J.FreitasT. T.McFarlinS. K.RutiglianoP. (2000). The timeline followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology, 68, 134-144.
26.
FiellinD. A.BarryD. T.SullivanL. E.CutterC. J.MooreB. A.O’ConnorP. G.SchottenfeldR. S. (2013). A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. The American Journal of Medicine, 126, 74.e11-74.e77.
27.
FiellinD. A.BarthwellA. G. (2003). Guideline development for office-based pharmacotherapies for opioid dependence. Journal of Addictive Diseases, 22, 109-120.
28.
FiellinD. A.PantalonM. V.ChawarskiM. C.MooreB. A.SullivanL. E.O’ConnorP. G.SchottenfeldR. S. (2006). Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine, 355, 365-374.
29.
FiellinD. A.PantalonM. V.PakesJ. P.O’ConnorP. G.ChawarskiM.SchottenfeldR. S. (2002). Treatment of heroin dependence with buprenorphine in primary care. The American Journal of Drug and Alcohol Abuse, 28, 231-241.
30.
FinchJ. W.KamienJ. B.AmassL. (2007). Two year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opiod dependence within a private practice setting. Journal of Addiction Medicine, 1, 104-110.
31.
FrenchM. T.ZarkinG. A.HubbardR. L.RachalJ. V. (1993). The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. The American Journal of Drug and Alcohol Abuse, 19, 19-33.
32.
FriedmannP. D.LemonS. C.SteinM. D.EtheridgeR. M.D’AunnoT. A. (2001). Linkage to medical services in the Drug Abuse Treatment Outcome Study. Medical Care, 39, 284-295.
33.
FudalaP.BridgeT.HerbertS.WillifordW.ChiangC.JonesK.. . . GroupB. N. C. S. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349, 949-958.
34.
GersteinD. R. (2004). Outcome research: Drug abuse. In GalanterM.KleberH. D. (Eds.), The American psychiatric press textbook of substance abuse treatment (3rd ed., pp. 169-180). Washington, DC: American Psychiatric Press
35.
GiffordE. V. (1994). Setting a course for behavior change: The verbal context of acceptance. In HayesS. C.JacobsonN. S.FolletteV. M.DougherM. J. (Eds.), Acceptance and change: Content and context in psychotherapy (pp. 218-222). Reno, NV: Context Press.
36.
GiffordE. V.AntonuccioD. O.KohlenbergB. S.HayesS. C.PiaseckiM. M. (November, 2002). Combining Bupropion SR with acceptance-based behavioral therapy for smoking cessation: Preliminary results from a randomized controlled trial. Paper presented at the annual meeting of the Association for Advancement of Behavior Therapy, Reno, NV.
37.
GiffordE. V.HayesS. C. (May, 1997). Discrimination training and the function of acceptance. Paper presented at the meeting of the Association for Behavior Analysis, Chicago, IL.
38.
GiffordE. V.KohlenbergB. S.HayesS. C.AntonuccioD. O.PiaseckiM. M.Rasmussen-HallM. L.PalmK. M. (2004). Acceptance-based treatment for smoking cessation. Behavior Therapy, 35, 689-705.
39.
GoldsteinR. Z.VolkowN. D. (2002). Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. American Journal of Psychiatry, 159, 1642-1652.
40.
HajekP.BelcherM.StapletonJ. (1987). Breath-holding endurance as a predictor of success in smoking cessation. Addictive Behaviors, 12, 285-288.
41.
HayesS. C. (1987). A contextual approach to therapeutic change. In JacobsonN. (Ed.), Psychotherapists in clinical practice (pp. 327-387). New York, NY: Guilford Press.
42.
HayesS. C. (2006). The Acceptance and Action Questionnaire-II. Unpublished manuscript.
43.
HayesS. C.AfariN.McCurryS. M.WilsonK. G. (May, 1990). The efficacy of comprehensive distancing in the treatment of agoraphobia. Paper presented at the annual meeting of the Association for Behavior Analysis, Nashville, TN.
44.
HayesS. C.StrosahlK. D.WilsonK. G. (1999). Acceptance and commitment therapy: An experiential approach to behavior change. New York, NY: Guilford Press.
45.
HayesS. C.WilsonK.GiffordE.BissettR.PiaseckiM.BattenS.. . . GreggJ. (2004). A preliminary trial of twelve-step facilitation and acceptance and commitment therapy with polysubstance-abusing methadone-maintained opiate addicts. Behavior Therapy, 35, 667-688.
46.
HendershotC. S.WitkiewitzK.GeorgeW. H.MarlattG. A. (2011). Relapse prevention for addictive behaviors. Substance Abuse Treatment, Prevention, and Policy, 6, Article 17.
47.
Hernandez-LopezM.LucianoM. C.BrickerJ. B.Roales-NietoJ. G.MontesinosF. (2009). Acceptance and commitment therapy for smoking cessation: A preliminary study of its effectiveness in comparison with cognitive behavioral therapy. Psychology of Addictive Behaviors, 23, 723-730.
48.
HoldwickD. J.Jr.WingenfeldS. A. (1999). The subjective experience of PASAT testing. Does the PASAT induce negative mood?Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychology, 14, 273-284.
49.
HorvathP. (1990). Treatment expectancy as a function of the amount of information presented in therapeutic rationales. Journal of Clinical Psychology, 46, 636-642.
50.
HubbardR. L.MarsdenM. E.RachalJ. V.HarwoodH. J.CavanaughE. R.GinzburgH. M. (1989). Drug abuse treatment: A national study of effectiveness. Chapel Hill: The University of North Carolina Press.
51.
HymanS. M.FoxH.HongK. I.DoebrickC.SinhaR. (2007). Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Experimental and Clinical Psychopharmacology, 15, 134-143.
52.
KazdinA. E.KrouseR. (1983). The impact of variations in treatment rationales on expectancies for therapeutic change. Behavior Therapy, 14, 657-671.
53.
LeeJ. D.GrossmanE.DiRoccoD.GourevitchM. N. (2009). Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine, 24, 226-232.
54.
LejuezC. W.ForsythJ. P.EifertG. H. (1998). Devices and methods for administering carbon dioxide-enriched air in experimental and clinical settings. Journal of Behavior Therapy and Experimental Psychiatry, 29, 239-248.
55.
LejuezC. W.PaulsonA.DaughtersS. B.BornovalovaM. A.ZvolenskyM. J. (2006). The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behaviour Research and Therapy, 44, 667-677.
56.
LeonA. C.DavisL. L.KraemerH. C. (2011). The role and interpretation of pilot studies in clinical research. Journal of Psychiatric Research, 45, 626-629.
57.
LingW.FarabeeD.LiepaD.WuL. T. (2012). The Treatment Effectiveness Assessment (TEA): An efficient, patient-centered instrument for evaluating progress in recovery from addiction. Substance Abuse and Rehabilitation, 3, 129-136.
58.
LingW.HillhouseM.AngA.JenkinsJ.FaheyJ. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction, 108, 1788-1798.
59.
LubmanD. I.YucelM.PantelisC. (2004). Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction, 99, 1491-1502.
60.
LuomaJ. B.HayesS. C.WalserR. (2007). Learning acceptance and commitment therapy: A skills training manual for therapists. Oakland, CA: New Harbinger Press.
61.
MagillM.RayL. A. (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. Journal of Studies on Alcohol and Drugs, 70, 516-527.
62.
MaguraS.LeeS. J.SalsitzE. A.KolodnyA.WhitleyS. D.TaubesT.. . . RosenblumA. (2007). Outcomes of buprenorphine maintenance in office-based practice. Journal of Addictive Diseases, 26, 13-23.
63.
MarschL. A.BickelW. K.BadgerG. J.JacobsE. A. (2005). Buprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing. Drug and Alcohol Dependence, 77, 195-204.
64.
MattickR. P.KimberJ.BreenC.DavoliM. (2004). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, (3), CD002207.
65.
MattickR. P.KimberJ.BreenC.DavoliM. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, Apr16 (2), CD002207.
66.
McLellanA. T.WoodyG. E.MetzgerD.McKayJ.DurrellJ.AltermanA. I.O’BrienC. P. (1996). Evaluating the effectiveness of addiction treatments: Reasonable expectations, appropriate comparisons. Milbank Quarterly, 74, 51-85.
67.
MintzerI. L.EisenbergM.TerraM.MacVaneC.HimmelsteinD. U.WoolhandlerS. (2007). Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Annals of Family Medicine, 5, 146-150.
68.
QuinnE. P.BrandonT. H.CopelandA. L. (1996). Is task persistence related to smoking and substance abuse? The application of learned industriousness theory to addictive behaviors. Experimental and Clinical Psychopharmacology, 4, 186-190.
69.
RobinsonT. E.BerridgeK. C. (2001). Incentive-sensitization and addiction. Addiction, 96, 103-114.
70.
SimonsJ. S.GaherR. M. (2005). The distress tolerance scale: Development and validation of a self-report measure. Motivation and Emotion, 29, 83-102.
71.
SoeffingJ. M.MartinL. D.FingerhoodM. I.JasinskiD. R.RastegarD. A. (2009). Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. Journal of Substance Abuse Treatment, 37, 426-430.
72.
SteinM. D.CioeP.FriedmannP. D. (2005). Buprenorphine retention in primary care. Journal of General Internal Medicine, 20, 1038-1041.
73.
SteinM. D.HermanD. S.KettavongM.CioeP. A.FriedmannP. D.TelliogluT.AndersonB. J. (2010). Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. Journal of Substance Abuse Treatment, 39, 157-166.
74.
StottsA. L.GreenC.MasudaA.GrabowskiJ.WilsonK.NorthrupT. F.. . . SchmitzJ. M. (2012). A stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug and Alcohol Dependence, 125, 215-222.
75.
StottsA. L.MasudaA.WilsonK. (2009). Using acceptance and commitment therapy during methadone dose reduction: Rationale, treatment description, and a case report. Cognitive and Behavioral Practice, 16, 205-213.
76.
StrongD. R.BrownR.SimsM.HermanD.AndersonB.SteinM. (2012). Persistence during stress-challenge associated with lapse to opiate use during buprenorphine treatment. Journal of Addiction Medicine, 6(3), 219-225.
77.
StrongD. R.LejuezC. W.DaughtersS.MarinelloM.KahlerC. W.BrownR. A. (2003). Computerized mirror tracing task version 1. Unpublished manual.
78.
Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 national survey on drug use and health: Summary of national findings (NSDUH Series H-44, HHS Publication No. (SMA) 12-4713). Rockville, MD: Author.
79.
TsuiJ. I.AndersonB. J.StrongD. R.SteinM. D. (2014). Craving predicts opioid use in opioid-dependent patients who initiating buprenorphine treatment: a longitudinal study. American Journal of Drug and Alcohol Abuse, 40, 163-169.
80.
TullM. T.SchulzingerD.SchmidtN. B.ZvolenskyM. J.LejuezC. W. (2007). Development and initial examination of a brief intervention for heightened anxiety sensitivity among heroin users. Behavior Modification, 31, 220-242.
81.
WessonD. R.LingW. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35, 253-259.
82.
WilsonK. G.SandozE. K.KitchensJ. (2010). The Valued Living Questionnaire: Defining and measuring valued action within a behavioral framework. The Psychological Record, 60, 249-272.
83.
WitkiewitzK.MarlattG. A. (2004). Relapse prevention for alcohol and drug problems: That was Zen, this is Tao. The American psychologist, 59, 224-235.
84.
ZettleR. D. (1984). Cognitive therapy of depression: A conceptual and empirical analysis of component and process issues (Unpublished doctoral dissertation). University of North Carolina, Greensboro.
85.
ZettleR. D.HayesS. C. (1986). Dysfunctional control by client verbal behavior: The context of reason-giving. The Analysis of Verbal Behavior, 4, 30-38.
86.
ZettleR. D.RainesJ. C. (1989). Group cognitive and contextual therapies in treatment of depression. Journal of Clinical Psychology, 45, 438-445.
